Keywords: ERYTECH Pharma, Orphan designation, Enhoxy, Graspa, EMA
ERYTECH Pharma gains EU orphan designation for Enhoxy
Article | 14 June 2012
French late-stage biopharma company ERYTECH Pharma says that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
